This is an open-label, pragmatic, single-dose study using matched controls in participants with mild to moderate COVID-19. Participants will track for developing symptoms while at home and upon reporting of symptoms will test for COVID-19. If positive for COVID-19, a one-time at-home infusion of Bamlanivimab (LY3819253) will be provided by Optum Infusion. Participants will then track for 28 days to assess for any additional medical care needed or if hospitalization was required.
Drug: bamlanivimab
Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab by a registered nurse. This infusion will last approximately 1 hour followed by 1 hour of observation.
Inclusion Criteria:
- UnitedHealthcare member
- confirmed COVID-19 positive
- located in an area where Bamlanivimab (LY3819253) is available for infusion
Exclusion Criteria:
- current (from first symptom report) hospitalization for COVID-19
- prior administration of Bamlanivimab or other COVID-19 therapies
- previous COVID-19 diagnosis
- prior receipt of a COVID-19 vaccine
- not authorized for patient use per the EUA
QueryLab
Minnetonka, Minnesota, United States
Dan Griffin, MD, PHD, Principal Investigator
ProHealth New York - UnitedHealth Group